Skip to main content
SpringerLink
Log in

Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis

  • Original Article
  • Published:
Journal of Infection and Chemotherapy

Abstract

Voriconazole (VRCZ) reportedly possesses a broad spectrum of antifungal activity against Aspergillus spp. and Candida spp., and the blood concentration of VRCZ is correlated with both the efficacy and the adverse effects of this drug. Monitoring of the blood concentration target level of VRCZ has not yet been widely adopted in the medical field, and no evidence concerning this target level has been reported. Accordingly, we used a meta-analysis to investigate the optimal blood concentration of VRCZ. Using data from 12 reports, we found that the success rate for fungal infection treatment increased significantly at VRCZ levels greater than 1.0 μg/ml when a graded cutoff value within the range of 1.0–3.0 μg/ml was used as the VRCZ trough blood concentration [odds ratio (OR) 7.23, 95% confidence interval (CI) 2.84–18.37, P < 0.0001]. Concerning the safety evaluation, the incidence of adverse neurological effects increased significantly at a cutoff value of 4.0 μg/ml when a graded cutoff value within the range of 3.0–6.0 μg/ml was used (OR 2.23, 95% CI 1.12–4.46, P = 0.02). However, in all 12 literature sources, an increasing incidence of liver dysfunction was reported at higher blood concentrations, and no accurate cutoff values were obtained. Consequently, a VRCZ trough blood concentration more than 1.0 μg/ml from the perspective of efficacy and less than 4.0 μg/ml from the perspective of safety is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Epinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109, 494) against opportunistic filamentous and dimorphic fungi and common and emerging pathogens. J Clin Microbiol. 1998;36:198–202.

    Google Scholar 

  2. Deep-Seated Mycosis Guidelines Editorial Committee. Guidelines for management of deep-seated mycosis 2007. Tokyo: Kyowakikaku; 2007 (in Japanese).

  3. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother. 2008;61:17–25.

    Article  PubMed  CAS  Google Scholar 

  4. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47:3165–9.

    Article  PubMed  CAS  Google Scholar 

  5. Wood N. Pharmacokinetics of Voriconazole. Jpn J Chemother. 2005;53:16–23.

    CAS  Google Scholar 

  6. Wang G, Lei HP, Li Z, Tan ZR, Guo D, Fan L, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009;65:281–5.

    Article  PubMed  CAS  Google Scholar 

  7. Common Terminology Criteria for Adverse Events (CTCAE) v3.0. http://www.jcog.jp/.

  8. Yamaguchi H. Antifungal activity of voriconazole. Jpn J Chemother. 2005;53:8–15.

    CAS  Google Scholar 

  9. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

    Article  PubMed  CAS  Google Scholar 

  10. Matsumoto K, Ikawa K, Abematsu K, Fukunaga N, Nishida K, Fukumizu T, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents. 2009;34:91–4.

    Article  PubMed  CAS  Google Scholar 

  11. Hagiwara E, Shiihara J, Matsushima A, Enomoto T, Tagawa A, Sekine A, et al. Usefulness of monitoring plasma voriconazole concentration in patients with chronic necrotizing pulmonary aspergillosis. Nihon Kokyuki Gakkai Zasshi. 2009;47:93–7.

    PubMed  Google Scholar 

  12. Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol. 2009;89:592–9.

    Article  PubMed  CAS  Google Scholar 

  13. Shimoeda S, Nakazawa K, Kobayashi H, Nakagawa S, Yamato S, Sasaki M, et al. Clinical significance of measuring serum concentrations of voriconazole in the hematological field. Jpn J Pharm Health Care Sci. 2008;34:638–43.

    Article  CAS  Google Scholar 

  14. Okuda T, Okuda A, Watanabe N, Takao M, Takayanagi K. Retrospective serological tests for determining the optimal blood concentration of voriconazole for treating fungal infection. Yakugaku Zasshi. 2008;128:1811–8.

    Article  PubMed  CAS  Google Scholar 

  15. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201–11.

    Article  PubMed  CAS  Google Scholar 

  16. Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006;136:739–42.

    PubMed  CAS  Google Scholar 

  17. Obata Y, Takada T, Tamura K. Zoukishikkan wo Kisosikkan tosita Shinsyusei Aspergillus reiniokeru Voriconazole no Yakubutukettyuunoudo Monitoring to Rinsyokouka. Jpn J Chemother. 2008;56:172.

    Google Scholar 

  18. Yoshida H, Sawada K, Tuzuki K, Suzumura Y, Oohira Y, Yoneyama E, et al. Voriconazole no TDM. Zisshi No Igi (Jpn J Pharmacol Ther). 2007;38:S239.

    Google Scholar 

  19. Takakura S, Sawada K, Fujiwara N, Saitoh T, Itoh Y, Iiinuma Y, et al. Voriconazole Kettyuu Noudo Monitoring no Hituyousei. Jpn J Chemother. 2006;54:56.

    Google Scholar 

  20. Denning BW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563–71.

    Article  PubMed  CAS  Google Scholar 

  21. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50:1570–2.

    Article  PubMed  CAS  Google Scholar 

  22. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46:235–43.

    Article  PubMed  CAS  Google Scholar 

  23. Niki Y, Yoshida M, Shimada K, Kohno S, Masaoka T, Yamaguchi H, et al. A clinical trial of voriconazole for deep-seated mycosis. An uncontrolled multicenter study. Jpn J Chemother. 2005;53:32–50.

    Google Scholar 

  24. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004;199:193–209.

    Article  PubMed  CAS  Google Scholar 

  25. Hamada Y, Komatsu T, Seto Y, Matsubara H, Kume H, Sunakawa K, et al. Liposomal-amphotericin B efficacy and safety. J Jpn Assoc Infect Dis. 2010;84:193–8.

    Google Scholar 

Download references

Acknowledgments

We wish to express our deep gratitude to each of the authors who contributed their valuable time in providing the databases necessary for this study.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Kitasato University East Hospital, 2-1-1, Asamizodai, Minamiku, Sagamihara, Kanagawa, 258-0380, Japan

    Yukihiro Hamada & Masakazu Kuroyama

  2. Department of Pharmacy, Kitasato University Hospital, Sagamihara, Japan

    Yoshinori Seto & Kazuo Yago

  3. Kitasato University School of Pharmaceutical Science, Tokyo, Japan

    Kazuo Yago & Masakazu Kuroyama

Authors
  1. Yukihiro Hamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshinori Seto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuo Yago
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masakazu Kuroyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yukihiro Hamada.

About this article

Cite this article

Hamada, Y., Seto, Y., Yago, K. et al. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. J Infect Chemother 18, 501–507 (2012). https://doi.org/10.1007/s10156-011-0363-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10156-011-0363-6

Keywords

Search

Navigation